The biomarker’s responsiveness to certain therapies, such as sacubitril/valsartan, and its interactions with treatment effects, as seen with β-blockers, suggest that Gal-3 may have a role in personalized HF management. The gene discussed is LGALS3; the disease is hydrops fetalis.